Asset profile
Melevodopa/carbidopa (Sirio) · Sirio
Small molecule
Evidence outlook · lead readout
NCT00491998 · Parkinson's Disease
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT00491998: The study was randomized and double-blind, with a planned enrollment of 27 participants and a comparison with standard levodopa/carbidopa tablets. However, its primary endpoint was a pharmacokinetic measure of plasma levodopa concentrations rather than a clinical or endoscopic outcome, and no primary endpoint results were posted.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.